NEW GPC Inc Pharmaceutical Import Profile — Guyana (DGFT 2022–2026)

Name: NEW GPC Inc Pharmaceutical Import Records from India — 3 Products, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

NEW GPC Inc — Pharmaceutical Importer Profile (2026) | 3 Products, $1.6M Trade | TransData Nexus

NEW GPC Inc

Pharmaceutical Importer · Guyana · Diabetes & Endocrine Focus · $1.6M Total Trade · DGFT Verified

NEW GPC Inc is a pharmaceutical importer based in Guyana with a total trade value of $1.6M across 3 products in 3 therapeutic categories. Based on 130 verified import shipments from Indian Customs (DGFT) records, NEW GPC Inc is the #1 buyer in 1 product including Plasma. NEW GPC Inc sources from 53 verified Indian suppliers, with H V A International accounting for 19.6% of imports.

NEW GPC Inc — Import Portfolio & Supplier Network

NEW GPC Inc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to NEW GPC Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
H V A International	$1.7M	1,579	19.6%
Macleods Pharmaceuticals Limited	$1.3M	88	15.8%
Reliance Life Sciences Private Limited	$943.5K	27

What Formulations Does NEW GPC Inc Import?

Formulation	Value	Ships
Pharmaceuticals medicines - cipro-500	$192.3K	4
Human normal immunoglobulin for	$155.8K	4
Chlorthone-25 (chlorthalidone tablets	$144.2K	3
Biosulin l (insulin zinc injectable	$140.6K	4
Biosulin 3070 (insulin INJ.biphasic	$125.9K	3
Human albumin solution b p 20 pct 50 ML(alburel 20% 50ML)	$124.2K	3
Biosulin 3070 (insulin injection	$100.0K	2
Cefuroxime 500 MG tablets	$100.0K	2
Salbutamol 100 MCG/dose	$100.0K	2
Drugs and pharmaceuticals harmlessmedicines rifampicin capsules BP 300 MG	$100.0K	2
Human albumin solution b.p.20 pct 50ML	$97.3K	2
Human albumin solution b.p. 20 pct 50ML(alburel 20% 50ML	$90.1K	2
Tenofovir alafenamide 25 MG tabs Each contains tenofovir	$85.9K	4
Biosulin 3070 insulin injection	$80.0K	2
Drugs and pharmaceuticals harmless	$73.3K	18

NEW GPC Inc imports 1,632 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Insulin	Diabetes & Endocrine	$900.0K	18	1.2%	13
2	Plasma	Other	$674.7K	110	22.8%	1
3	Raltegravir	Antiviral & HIV Medications	$36.3K	2	0.6%	7

NEW GPC Inc imports 3 pharmaceutical products across 3 categories into Guyana totaling $1.6M. The company is the #1 buyer for 1 product: Plasma.

NEW GPC Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

NEW GPC Inc. is a private pharmaceutical company headquartered at Lot A1 Farm, East Bank Demerara, Guyana. Established in December 1999 following the privatization of the Guyana Pharmaceutical Corporation Ltd., the company inherited all assets, including proprietary rights to intellectual property, from its predecessor. Its mission is to supply products that improve consumer health, create value for stakeholders, and build brands synonymous with quality. The company aims to be the market leader in pharmaceutical products both locally and regionally.

NEW GPC Inc. carries on a ninety-year tradition as the Caribbean’s oldest and largest pharmaceutical manufacturer of generic pharmaceuticals and over-the-counter preparations of the highest quality. The company provides products of internationally recognized standards in a cost-effective and environmentally responsible manner, satisfying local and overseas demands for ethically produced proprietary generic and over-the-counter products using the latest innovative technology.

2Distribution Network

NEW GPC Inc. operates a comprehensive distribution network within Guyana and extends its reach to international markets. The company's manufacturing plant is located at Farm, East Bank Demerara, on the outskirts of Georgetown. This facility spans five acres and comprises several sectors, including administrative offices, warehouse facilities, manufacturing units, and maintenance buildings. The plant is designed to adhere to current Good Manufacturing Practices (cGMP), ensuring the production of high-quality pharmaceutical products.

While specific details about the company's logistics capabilities and warehouse locations beyond the main manufacturing plant are not publicly disclosed, NEW GPC Inc. has established partnerships with distributors in various regions, including the United States. For instance, Health International Inc. operates in Georgetown, Guyana, and America Futurecare Inc. and Global Imports & Distribution Corp. are based in the USA, indicating a strategic approach to expanding its distribution network.

3Industry Role

NEW GPC Inc. plays a multifaceted role in Guyana's pharmaceutical supply chain. As a manufacturer, it produces a wide range of generic pharmaceuticals and over-the-counter products, including cough, cold, and flu medications, pain relievers, and household products. The company also imports finished pharmaceutical formulations from India, indicating its role as both a manufacturer and an importer. This dual role allows NEW GPC Inc. to meet the diverse healthcare needs of the Guyanese population and maintain a significant presence in the regional pharmaceutical market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — NEW GPC Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

NEW GPC Inc.'s sourcing strategy from India reveals a high degree of supplier concentration. The company has engaged with 53 unique Indian suppliers, with the top five accounting for 100% of its imports. H V A International leads with $1.7 million across 1,579 shipments, followed by MACLEODS Pharmaceuticals Limited at $1.3 million from 88 shipments, and Reliance Life Sciences Private Limited at $944,000 from 27 shipments. This concentration suggests a strategic choice to maintain strong, stable relationships with a select group of suppliers, potentially ensuring consistent product quality and supply reliability.

However, such concentration also poses risks, including dependency on a limited number of suppliers and potential vulnerabilities to supply chain disruptions. The extensive number of shipments (1,632 unique formulations) indicates a diverse product range, which may help mitigate some risks associated with supplier concentration. Nonetheless, the company's reliance on a few key suppliers underscores the importance of robust supplier relationship management and contingency planning to address potential disruptions.

2Supply Chain Resilience

NEW GPC Inc.'s supply chain resilience is influenced by its sourcing strategy from India. The company's extensive engagement with 53 unique suppliers and 1,632 unique formulations suggests a diversified product portfolio, which can enhance resilience against supply chain disruptions. However, the high concentration of imports from a select group of suppliers indicates potential vulnerabilities. The company's adherence to current Good Manufacturing Practices (cGMP) in its manufacturing facility demonstrates a commitment to quality and regulatory compliance, which is crucial for maintaining supply chain integrity.

Importing Pharmaceuticals into Guyana — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Guyana

1Regulatory Authority & Framework

In Guyana, the Government Analyst – Food and Drugs Department (GA-FDD), operating under the Ministry of Health, serves as the primary regulatory authority overseeing pharmaceutical imports. The GA-FDD is responsible for evaluating the safety, efficacy, and quality of pharmaceutical products before granting approval for importation and sale within the country.

Key legislation governing pharmaceutical imports in Guyana includes the Customs Act and the Value-Added Tax (VAT) Act. Pharmacies and licensed importers are eligible for partial customs exemptions and zero-rating of VAT on pharmaceuticals approved by the GA-FDD. To import pharmaceuticals, companies must obtain an import license and ensure compliance with the GA-FDD's requirements, including product registration and adherence to Good Manufacturing Practices (GMP). (gra.gov.gy)

2Import Licensing & GMP

Import licensing in Guyana requires pharmaceutical companies to obtain an import license from the Guyana Revenue Authority (GRA). Applicants must provide a Taxpayer Identification Number, an invoice or quotation, and a permit from the GA-FDD to import registered pharmaceuticals. The GA-FDD evaluates the safety, efficacy, and quality of pharmaceutical products before granting approval for importation and sale within the country. (gra.gov.gy)

Good Manufacturing Practices (GMP) certification is essential for pharmaceutical companies operating in Guyana. The GA-FDD requires that imported pharmaceuticals comply with GMP standards to ensure product quality and safety. Recognized GMP certifications include those from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Pharmaceutical companies must ensure that their products meet these standards to gain approval for importation and sale in Guyana.

NEW GPC Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

NEW GPC Inc.'s product strategy focuses on therapeutic areas with significant market demand in Guyana. The company's imports from India are primarily in the Diabetes & Endocrine category (55.9%), Other category (41.9%), and Antiviral & HIV Medications (2.3%). The top imported products include Plasma ($675K, Rank #1, 22.8% share), Insulin ($900K, Rank #13, 1.2% share), and Raltegravir ($36K, Rank #7, 0.6% share).

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — NEW GPC Inc

What products does NEW GPC Inc import from India?

NEW GPC Inc imports 3 pharmaceutical products across 3 categories. Top imports: Insulin ($900.0K), Plasma ($674.7K), Raltegravir ($36.3K).

Who supplies pharmaceuticals to NEW GPC Inc from India?

NEW GPC Inc sources from 53 verified Indian suppliers. The primary supplier is H V A International (19.6% of imports, $1.7M).

What is NEW GPC Inc's total pharmaceutical import value?

NEW GPC Inc's total pharmaceutical import value from India is $1.6M, based on 130 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does NEW GPC Inc focus on?

NEW GPC Inc imports across 3 categories. The largest: Diabetes & Endocrine (55.9%), Other (41.9%), Antiviral & HIV Medications (2.3%).

Get Full NEW GPC Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.